CytoSorbents Corporation (CTSO)

[cars100cars]

Before we know the cardiac surgery data, Dr. Chan has said he will follow protocol by presenting it first to FDA, then next to a formal cardiac doc conference. He doesn't want to step on the FDA's toes or slight medical professionals. However, on the last conference call, he described the data as "promising" -- perhaps a euphemism for "positively lowering free hemoglobin and lowering inflammation post cardiac surgery for better patient outcomes" -- but he couldn't say those words publicly yet. He also said CTSO expected to start a pivotal FDA trial in the next few months, with possible FDA approval coming in 2018. All very good signals to investors.